Duality Advisers LP bought a new stake in Thermo Fisher Scientific Inc. (NYSE:TMO) during the second quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission (SEC). The fund bought 4,143 shares of the medical research company’s stock, valued at approximately $1,501,000.
Other institutional investors and hedge funds also recently added to or reduced their stakes in the company. Laurel Wealth Advisors LLC increased its position in shares of Thermo Fisher Scientific by 104.3% during the 1st quarter. Laurel Wealth Advisors LLC now owns 94 shares of the medical research company’s stock worth $27,000 after purchasing an additional 48 shares during the last quarter. Stonehage Fleming Financial Services Holdings Ltd acquired a new position in Thermo Fisher Scientific during the first quarter worth $28,000. Ballast Advisors LLC bought a new stake in Thermo Fisher Scientific during the first quarter worth $35,000. Investors Research Corp lifted its stake in Thermo Fisher Scientific by 100.0% in the second quarter. Investors Research Corp now owns 120 shares of the medical research company’s stock valued at $39,000 after acquiring an additional 60 shares during the last quarter. Finally, Liberty One Investment Management LLC bought a new position in shares of Thermo Fisher Scientific in the 2nd quarter valued at about $41,000. Institutional investors and hedge funds own 87.51% of the company’s stock.
In related news, COO Mark Stevenson sold 25,000 shares of Thermo Fisher Scientific stock in a transaction that occurred on Friday, July 24th. The stock was sold at an average price of $404.58, for a total transaction of $10,114,500.00. Following the transaction, the chief operating officer now owns 73,621 shares of the company’s stock, valued at $29,785,584.18. The sale was disclosed in a legal filing with the SEC, which can be accessed through this link. Also, VP Syed A. Jafry sold 20,513 shares of the stock in a transaction on Monday, July 27th. The shares were sold at an average price of $414.94, for a total value of $8,511,664.22. Following the completion of the sale, the vice president now directly owns 26,657 shares of the company’s stock, valued at $11,061,055.58. The disclosure for this sale can be found here. Insiders sold 171,031 shares of company stock worth $67,284,857 over the last ninety days. Insiders own 0.44% of the company’s stock.
Several brokerages have recently commented on TMO. BTIG Research raised their target price on shares of Thermo Fisher Scientific from $372.00 to $475.00 and gave the stock a “buy” rating in a report on Thursday, July 23rd. SVB Leerink lifted their target price on shares of Thermo Fisher Scientific from $365.00 to $455.00 and gave the stock an “outperform” rating in a research report on Thursday, July 23rd. Needham & Company LLC lifted their target price on Thermo Fisher Scientific from $415.00 to $468.00 and gave the stock a “buy” rating in a report on Thursday, July 23rd. Argus raised their price target on shares of Thermo Fisher Scientific from $370.00 to $450.00 in a report on Monday, July 27th. Finally, Cleveland Research raised Thermo Fisher Scientific from a “neutral” rating to a “buy” rating in a research note on Wednesday, July 15th. Three research analysts have rated the stock with a hold rating and twelve have assigned a buy rating to the company. Thermo Fisher Scientific currently has an average rating of “Buy” and an average price target of $420.50.
Shares of Thermo Fisher Scientific stock opened at $413.95 on Friday. The stock has a market capitalization of $163.49 billion, a PE ratio of 44.80, a price-to-earnings-growth ratio of 1.85 and a beta of 1.04. Thermo Fisher Scientific Inc. has a 52 week low of $250.21 and a 52 week high of $420.99. The stock has a 50 day moving average price of $373.97 and a two-hundred day moving average price of $335.37. The company has a debt-to-equity ratio of 0.69, a quick ratio of 2.02 and a current ratio of 2.62.
Thermo Fisher Scientific (NYSE:TMO) last issued its earnings results on Wednesday, July 22nd. The medical research company reported $3.89 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $2.67 by $1.22. Thermo Fisher Scientific had a return on equity of 18.18% and a net margin of 14.12%. The company had revenue of $6.92 billion for the quarter, compared to analysts’ expectations of $6.91 billion. During the same period last year, the business earned $3.04 EPS. Research analysts forecast that Thermo Fisher Scientific Inc. will post 14.95 EPS for the current year.
The firm also recently disclosed a quarterly dividend, which will be paid on Thursday, October 15th. Shareholders of record on Tuesday, September 15th will be paid a $0.22 dividend. This represents a $0.88 dividend on an annualized basis and a dividend yield of 0.21%. The ex-dividend date is Monday, September 14th. Thermo Fisher Scientific’s dividend payout ratio (DPR) is 7.13%.
About Thermo Fisher Scientific
Thermo Fisher Scientific Inc provides analytical and other instruments, laboratory equipment, software, consumables, reagents, instrument systems, chemicals, supplies, and services under the Thermo Scientific, Applied Biosystems, Invitrogen, Fisher Scientific, and Unity Lab Services brands worldwide.
Read More: QQQ ETF
Receive News & Ratings for Thermo Fisher Scientific Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Thermo Fisher Scientific and related companies with MarketBeat.com's FREE daily email newsletter.